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Abstract
Background: Clinical trials in chronic pain often collect information about interference with work as answers to
component questions of commonly used questionnaires but these data are not normally analysed separately.
Methods: We performed a meta-analysis of individual patient data from four large trials of pregabalin for
fibromyalgia lasting 8-14 weeks. We analysed data on interference with work, inferred from answers to component
questions of Fibromyalgia Impact Questionnaire (FIQ), Short Form 36 Health Survey, Sheehan Disability Scale, and
Multidimensional Assessment of Fatigue, including “How many days in the past week did you miss work, including
housework, because of fibromyalgia?” from FIQ. Analyses were performed according to randomised treatment
group (pregabalin 150-600 mg daily or placebo), pain improvement (0-10 numerical pain rating scale scores at trial
beginning vs. end), and end of trial pain state (100 mm visual analogue pain scale [VAS]).
Results: Comparing treatment group average outcomes revealed modest improvement over the duration of the
trials, more so with active treatment than with placebo. For the ‘work missed’ question from FIQ the change for
patients on placebo was from 2.2 (standard deviation [SD] 2.3) days of work lost per week at trial beginning to 1.9
(SD 2.1) days lost at trial end (p < 0.01). For patients on 600 mg pregabalin the change was from 2.1 (SD 2.2) days
to 1.6 (SD 2.0) days (p < 0.001). However, the change in days of work lost was substantial in patients with a good
pain response: from 2.0 (SD 2.2) days to 0.97 (SD 1.6) days (p < 0.0001) for those experiencing >/= 50% pain
improvement and from 1.9 (SD 2.2) days to 0.73 (SD 1.4) days (p < 0.0001) for those achieving a low level of pain
at trial end (<30 mm on the VAS). Patients achieving both >/= 50% pain improvement and a pain score <30 mm
on the VAS had the largest improvement, from 2.0 (SD 2.2) days to 0.60 (SD 1.3) days (p < 0.0001). Analysing
answers to the other questions yielded qualitatively similar results.
Conclusions: Effective pain treatment goes along with benefit regarding work. A reduction in time off work >1
day per week can be achieved in patients with good pain responses.
Background
Fibromyalgia is a common chronic pain condition. It
occurs in 1-2% of the population, more often in women
than in men [1-3]. Chronic pain conditions such as
fibromyalgia have profound effects on quality of life
[4-6] and lead to interference with work and loss of pro-
ductivity [7-13].
In clinical trials of treatments for chronic painful con-
ditions - including trials in fibromyalgia - data on time
off work and interference with work are typically col-
lected as answers to component questions of commonly
used questionnaires. Answers from these component
questions are used to calculate overall scores of the
questionnaires, but are not usually analysed separately
and specifically with regard to work-related outcomes.
Such an analysis - though not originally intended by the
inventors of the questionnaires or the triallists who used
them - nonetheless has the potential to provide useful
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ment: Do the patients with the greatest improvement in
pain scores over the duration of the trial and those who
have the lowest levels of pain at trial end also have the
largest benefit with regard to work? How large is the
benefit? Do patients with no or little pain improvement
and high end of trial pain scores achieve any meaningful
benefit regarding work?
We have recently addressed the question whether ben-
efit in chronic pain trials across different domains of life
occurs in the same patients, using a large set of indivi-
dual patient data from randomised controlled trials
(RCTs) of pregabalin in fibromyalgia [14]. We found
that those patients with the largest pain improvement
(difference in pain intensity at trial beginning vs. end)
also had the largest benefit with regard to quality of life
and time off work. The study presented here builds on
our previous results. Using the same dataset we present
new analyses specifically relating to work. We investi-
g a t e dt i m eo f fw o r ka n di n t e r f e r e n c ew i t hw o r ki n
patients with fibromyalgia based on data from work-
related component questions from commonly used
questionnaires. Analyses were conducted by randomised
treatment group (pregabalin at doses of 150-600 mg per
day or placebo), pain improvement (comparing pain
intensity at the beginning and the end of trials), and
final (end of trial) pain state.
We analysed answers to work-related component
questions from different questionnaires commonly used
in chronic pain trials all addressing work but using dif-
ferent wording and assessment scales. Our aims were
threefold: first, to illuminate the relationship between
pain treatment, pain response, and work; second, to
investigate the comparability of answers to work-related
questions from different questionnaires; and, third, to
p r o v i d eaf r a m e w o r kf o rf u t u r ea n a l y s e so fd a t ao n
work-related outcomes collected in clinical trials in
chronic painful conditions.
Methods
We performed a meta-analysis of individual patient data
from four large trials of pregabalin for fibromyalgia last-
ing 8-14 weeks, analysing data on interference with
work, inferred from answers to component questions of
Fibromyalgia Impact Questionnaire (FIQ), Short Form
36 Health Survey (SF-36), Sheehan Disability Scale
(SDS), and Multidimensional Assessment of Fatigue
(MAF), including “How many days in the past week did
you miss work, including housework, because of fibro-
myalgia?” from FIQ. Analyses were performed according
to randomised treatment group (pregabalin at 150-600
mg daily or placebo), pain improvement (comparing 0-
10 numerical pain rating scale scores at trial beginning
and end), and end of trial pain state (100 mm visual
analogue pain scale [VAS]).
Pfizer Inc. provided Excel files containing individual
patient data from four RCTs of pregabalin (Lyrica) in
the treatment of fibromyalgia along with PDF files of
the corresponding clinical trial reports. Pfizer study ID
numbers of these trials and ClinicalTrials.gov identifier
numbers (where available) were as follows:
￿ 1008-105 [15]
￿ A0081056, NCT00645398 [16]
￿ A0081077, NCT00230776 [17]
￿ A0081100, NCT00333866 [18]
An enriched enrolment randomised withdrawal trial,
the “FREEDOM trial” [19], was not included in our ana-
lysis because it was of fundamentally different trial
design [20].
Patients in the four included trials were at least 18
years old, fulfilling American College of Rheumatology
classification criteria for fibromyalgia (1990 classification
criteria) and with pain scores of ≥40 mm on the 100
mm VAS after stopping any relevant pain or sleep medi-
cation. Patients were randomised to receive pregabalin
(150 mg, 300 mg, 450 mg, or 600 mg per day), or pla-
cebo, predominantly with a 2-week dose escalation
phase followed by fixed dosing for up to 14 weeks of
total trial duration. The minimum requirement for
inclusion in this individual patient meta-analysis was
that trials had to be both randomised and double blind.
Trial and patient characteristics are detailed in Addi-
tional file 1. In the four trials 2757 patients aged
between 18 and 82 years were treated with pregabalin
or placebo. More than 90% of trial participants were
women. One trial lasted 8 weeks (trial 1008-105); the
others lasted 13 or 14 weeks. Pregabalin doses of 300
mg (685 patients) and 450 mg (687 patients) were used
in all four trials, 600 mg (564 patients) in three, and 150
mg (132 patients) in one trial; placebo was given to 689
patients. Trial quality was assessed using the Oxford
Quality Scale [21]. Validity was scored using the Oxford
Pain Validity Scale [22]. All trials obtained the maxi-
mum scores of 5/5 and 16/16 on these scales, indicating
high trial quality and validity.
We analysed individual patient data on pain scores
and time off work or interference with work obtained at
the beginning of the trials (baseline measurements) and
at the end of trials. Data on time off work or interfer-
ence with work were compared
￿ according to randomised treatment group (placebo
or pregabalin at doses of 150, 300, 450, or 600 mg
per day),
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the comparison of baseline numerical pain rating
scores (scale 0-10) with end of trial numerical pain
rating scores (assessed after 8 weeks of treatment in
trial 1008-105 and after 12 weeks of treatment in
the three other trials), and
￿ according to pain state at end of trial, as assessed
by the VAS pain score on a 0-100 mm scale.
Not all questionnaires were used in all trials and not
all patients had usable individual patient data available.
Therefore the number of patients contributing to indivi-
dual analyses differed. Numbers of patients contributing
are given in Tables 1-2 and Figures 1-2.
Cut-off levels for pain improvement and end of trial
pain state were chosen with clinical relevance in mind
and were based on published evidence. The Initiative
on Methods, Measurement, and Pain Assessment in
Clinical Trials (IMMPACT) defined benchmarks for
interpreting change in chronic pain clinical trial out-
come measures [23]: a ‘minimally important’ improve-
ment was defined as a 10-20% decrease in pain
intensity, a ‘moderately important’ improvement was
defined as at least 30% decrease, and a ‘substantial’
improvement equated to at least 50% decrease in pain
intensity. This formed the basis for our approach to
classify improvement in pain intensity as 0-<15%, 15-
<30%, 30-<50%, ≥50%, or worsening. Furthermore,
pain greater than about 30 mm on a 100 mm VAS is
equivalent to ‘moderate’ or greater pain [24,25] and
therefore a pain level below 30 mm appears to be a
suitable clinical target. Hence 0-30 mm was chosen as
the strictest category of end of trial pain state and
was compared with the pain states >30-50 mm and
>50 mm.
We also analysed time off work and interference with
work according to whether patients achieved the status
of a ‘state responder’ (end of trial VAS pain score of 30
mm or less), ‘improvement responder’ (at least 50%
improvement in numerical pain rating scale score over
the duration of the trials), ‘double responder’ (state and
improvement responder), or ‘non-responder’ (neither
state nor improvement responder).
This approach was applied to the following five com-
ponent questions from four commonly used question-
naires:
￿“ How many days in the past week did you miss
work, including housework, because of fibromyal-
gia?” (scale 0-7) from the FIQ;
￿“ When you worked, how much did pain or other
fibromyalgia symptoms interfere with your ability to
do your work, including housework?” (scale 0-10)
from the FIQ;
￿“ During the past 4 weeks, how much did pain
interfere with your normal work (including both
work outside the home and housework)?” (scale 1-5)
from the SF-36;
Table 1 Days of work missed
Mean number (SD) of days of work missed per
week at trial beginning
Mean number (SD) of days of work missed
per week at trial end
Statistical
significance
Pregabalin dose (n)
Placebo (557) 2.2 (2.3) 1.9 (2.1) **
300 mg (547) 2.4 (2.3) 1.9 (2.1) ****
450 mg (553) 2.1 (2.2) 1.7 (2.0) ***
600 mg (561) 2.1 (2.2) 1.6 (2.0) ***
Pain improvement
(n)
Pain worse (221) 1.9 (2.1) 1.9 (2.1) NS
0-15% (281) 2.5 (2.4) 2.2 (2.2) NS
15-30% (233) 2.4 (2.2) 1.7 (2.0) ***
30-50% (319) 2.1 (2.2) 1.1 (1.7) ****
≥50% (435) 2.0 (2.2) 0.97 (1.6) ****
VAS pain score at
trial end (n)
>50 mm (1042) 2.4 (2.3) 2.1 (2.1) *
>30-50 mm (340) 1.9 (2.0) 1.1 (1.7) ****
0-30 mm (436) 1.9 (2.2) 0.73 (1.4) ****
Days of work missed per week at the beginning and end of trials as assessed by the question “How many days in the past week did you miss work, including
housework, because of fibromyalgia?” from the Fibromyalgia Impact Questionnaire (FIQ). Data are presented according to daily pregabalin dose, according to
improvement in pain intensity scores over the course of the trials, and according to pain state at end of the trials; statistical significance for the comparison of
trial end vs. beginning: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, NS - no significant difference. FIQ data were not available for trial 105, the only trial
with a 150 mg pregabalin group. Therefore no data for participants treated with 150 mg pregabalin are presented here.
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Mean score (SD) at trial beginning Mean score (SD) at trial end Statistical significance
Pregabalin dose (n)
Placebo (556) 6.8 (2.1) 5.6 (2.6) ****
300 mg (551) 6.7 (2.1) 5.5 (2.6) ****
450 mg (553) 6.7 (2.1) 5.3 (2.6) ****
600 mg (562) 6.7 (2.1) 5.5 (2.7) ****
Pain improvement (n)
Pain worse (221) 6.3 (2.2) 6.1 (2.2) NS
0-15% (282) 7.2 (1.9) 6.5 (2.2) ****
15-30% (233) 6.8 (2.1) 5.7 (2.3) ****
30-50% (319) 6.6 (1.9) 4.2 (2.3) ****
≥50% (435) 6.6 (2.2) 3.5 (2.6) ****
VAS pain score at trial end (n)
>50 mm (1046) 7.0 (2.0) 6.5 (2.1) ****
>30-50 mm (326) 6.3 (2.1) 4.5 (2.0) ****
0-30 mm (387) 6.3 (2.2) 2.8 (2.3) ****
Interference with work as assessed by the question “When you worked, how much did pain or other fibromyalgia symptoms interfere with your ability to do
your work, including housework?” (scale 0-10) from the Fibromyalgia Impact Questionnaire. Data are presented according to daily pregabalin dose, according to
improvement in pain intensity scores over the course of the trials, and according to pain state at end of the trials; abbreviations as in Table 1.
Figure 1 Days of work missed. Days of work missed per week at the beginning and end of trials as assessed by the question “How many days
in the past week did you miss work, including housework, because of fibromyalgia?” from the Fibromyalgia Impact Questionnaire (FIQ). Data are
presented as a comparison of ‘state’ and ‘improvement’ responders; ‘non-responders’ are neither state nor improvement responders; ‘double
responders’ are both. ** p < 0.01, *** p < 0.001, **** p < 0.0001, NS - no significant difference, SD - standard deviation. FIQ data were not
available for trial 105, the only trial with a 150 mg pregabalin group. Therefore no data for participants treated with 150 mg pregabalin are
presented here.
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work” (scale 0-10) from the SDS;
￿“ In the past week, to what degree has fatigue inter-
fered with your ability to work?” (scale 1-10) from
the MAF.
Spreadsheet calculations from the individual patient
data were performed independently of Pfizer by one of
the authors: Jocelyn Paine from the commercial spread-
sheet calculating and programming service ‘Spreadsheet
Factory’ [26]. The statistical significance of differences in
mean values at the beginning and end of trials was
established with the t test using ‘QuickCalcs’ [27].
Results
Days of work lost per week
B a s e do nr e s p o n s ed a t af r o mt h eq u e s t i o n“How many
days in the past week did you miss work, including
housework, because of fibromyalgia?” from the FIQ we
compared placebo and pregabalin treatment arms of the
trials (Table 1). There was statistically significant
improvement at trial end (compared with the baseline
values at trial beginning) in all treatment arms, includ-
ing in the patients treated with placebo, though greater
improvement occurred with pregabalin treatment.
While the analysis of patients according to rando-
m i s e dt r e a t m e n tg r o u p( a n di r r e s p e c t i v eo fp a i n
response) reveal only modest average improvements
when trial beginning and end were compared, analysing
patients according to pain improvement revealed sub-
stantial differences. Those patients with the largest pain
improvements (changes in 0-10 numerical pain rating
scale score from trial baseline to trial end) also had the
largest changes in days off work. Those with at least
50% pain improvement gained about one day of work
per week (Table 1).
Analysing days off work by end of trial pain state (100
mm VAS score) likewise revealed a close relationship
between pain experience and time off work. While there
was little difference in time off work in those with a
final VAS pain state >50 mm, those with a pain state
>30-50 mm benefited substantially, and patients with a
final pain state of 0-30 mm benefited extensively, gain-
ing about 1.3 days of work per week (Table 1).
Next we analysed time off work according to status as
a ‘state responder’, ‘improvement responder’, ‘double
responder’ or ‘non-responder’ (Figure 1). Patients who
were neither state nor improvement responders had the
least benefit in term of gaining time at work. Patients
who were improvement but not state responders bene-
fited more and those who were state but not improve-
ment responders had even more benefit. Double
responders had the largest benefit, with an average of
1.4 more days of work per week
Figure 2 Interference with work. Interference with work as assessed by the question “When you worked, how much did pain or other
fibromyalgia symptoms interfere with your ability to do your work, including housework?” from the Fibromyalgia Impact Questionnaire;
responder categories and abbreviations as in Figure 1.
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We analysed answers to the question “When you
worked, how much did pain or other fibromyalgia symp-
toms interfere with your ability to do your work, includ-
ing housework?” from the FIQ in an analogous manner
to answers to the question about days of work missed.
Our findings were similar: Analysing all patients inde-
pendently of pain outcomes there was improvement
with regard to work over the duration of the trials in
every treatment group, more so with pregabalin than
with placebo, though the differences were not large.
Those with the most pain improvement and the least
end of trial pain scores had the best outcome in terms
of experiencing less interference with work, while those
with little pain improvement and high end of trial pain
scores had little benefit (Table 2). Double-responders
had the largest benefit with a 67% reduction in average
work interference, followed by state only responders
(55%), improvement only responders (27%), and non-
responders (12%; Figure 2).
Other questions about interference with work
The answers to the component questions about interfer-
ence with work from the other questionnaires produced
a similar picture. Categorising patients by randomised
treatment group (pregabalin 150, 300, 450, or 600 mg or
placebo) revealed modest improvement when trial
beginning and end were compared, somewhat more so
in the pregabalin groups than with placebo (data not
shown).
Analyses of state and improvement responders like-
wise yielded qualitatively similar results. We investigated
between-question similarity by calculating the percent
improvement in answers to the different work-related
questions, in each case comparing responses at trial
beginning and end. We performed these analyses
according to pain improvement over the duration of the
trials (Table 3) and according to end of trial pain state
(Table 4). For example, patients in the category of ≥50%
improvement in pain score had a 52% improvement in
the score for the FIQ question about days of work
missed and 47% improvement in work interference as
assessed from the FIQ question; those in the category of
30-50% pain improvement had an improvement in the
answers to those questions of 47% and 36% respectively.
Lower levels of pain benefit were associated with smaller
reductions in work interference, and patients without
pain improvement had no meaningful improvement
either with regard to days of work missed or with regard
to interference with work in any question (Table 3). The
pattern of higher levels of pain intensity reduction being
associated with greater reductions in work interference
was found for questions from all four questionnaires
(FIQ, SF-36, SDS, and MAF). The degree of benefit was
similar in the three questionnaires using a 0-10 or 1-10
scale (FIQ, SDS, and MAF), with somewhat less benefit
for SF-36, using a five-point scale.
Patients with an end of trial pain state of 30 mm or
less on the 0-100 mm VAS had an improvement in the
score for the FIQ questions about days of work missed
and work interference of 61% and 56%, respectively.
Those with a final VAS score >50 mm only had minimal
improvement in days of work lost and work interference
(Table 4). Again, less pain was associated with greater
improvement in work interference for all questions, and
the degree of benefit was similar in the three question-
naires using a 0-10 or 1-10 scale (FIQ, SDS, and MAF),
with somewhat less apparent benefit for SF-36 where a
five-point scale was used.
Discussion
Analysis of data at the level of the individual patient can
reveal insights over and above those that can be
obtained from the analysis of group mean values but it
is only possible when trial data are made available at the
level of the individual patient. We had such data for
pregabalin trials in fibromyalgia, but not for pregabalin
in other painful conditions, nor for other drugs in fibro-
myalgia or other painful conditions. The availability of
clinical trial data at the level of the individual patient is
uncommon, especially where trials have consistently
used several different assessment scales permitting ana-
lysis of the relationship between treatment success as
measured by pain relief and work interference.
Table 3 Improvement in answers to work-related questions according to pain improvement
Pain
improvement
FIQ (days of work
missed)
FIQ (interference with
work)
SF-36 (interference with
work)
SDS (interference with
work)
MAF (interference with
work)
≥ 50% 52 47 33 62 57
30 - <50% 47 36 23 42 35
15 - <30% 28 16 16 28 28
0 - <15% 12 10 8.2 12 0.95
<0% -1.0 2.8 1.8 -6.9 -10
Percent improvement in answers to work-related questions over the duration of the trials; patients were categorised by pain improvement (based on the 0-10
numerical pain rating scale comparing trial beginning and end); FIQ - Fibromyalgia Impact Questionnaire, SF-36 - Short Form 36 Health Survey, SDS - Sheehan
Disability Scale, MAF - Multidimensional Assessment of Fatigue.
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work in trials of pregabalin for fibromyalgia is obtained
by patients who have large improvements in pain inten-
sity, achieve a low level of pain after treatment, and
especially if they achieve both of these outcomes. Com-
paring treatment groups irrespective of pain outcomes
reveals a picture of only modest average benefit of active
treatment when compared with placebo. However, sub-
stantial benefit in work-related outcomes can be demon-
strated in those for whom treatment ‘works’ in the sense
that it leads to a reduction in pain or a low end of trial
pain state. Relationships between higher levels of pain
and increased disability and interference with activities
have been shown for a variety of conditions including
cancer pain, phantom limb pain, back pain, and carpal
tunnel syndrome [28-30], but improvements in work-
related endpoints on return to a low pain state are less
well described.
The point that fibromyalgia leads to substantial inter-
ference with work is well worth making. The status of
fibromyalgia as a valid disease entity, let alone one with
a substantial impact on a variety of domains of life, has
long been in question because a clear physical correlate
of the disease could not be demonstrated. Not surpris-
ingly, in the face of such scepticism the diagnosis of
fibromyalgia is often delayed [13]. Recently, however,
evidence pointing to objective changes is accumulating
[31]. A link between elevated intrinsic brain connectivity
and spontaneous pain intensity in fibromyalgia has been
shown [32], as has an association between cerebral
blood flow and response to treatment with gabapentin
[33]. Along with the emerging evidence of a physical
correlate comes the insight that fibromyalgia has real
and profound impact across different domains of life
including work [8-10,12,13] and that the economic bur-
den associated with fibromyalgia is substantial, also
because of a high prevalence of co-morbidities [34]. Dis-
ease state and interference with work are linked in fibro-
myalgia, as the present and other studies demonstrate.
Temporary work disability in fibromyalgia patients has
been associated with a worse clinical situation and
worse functional capacity [35]. A narrative interview
study uncovered that severe pain and fatigue, together
with a demanding life situation and ageing, seemed to
cause substantial interference with work and functioning
[36]. Remaining at work despite fibromyalgia requires ‘a
constant struggle’ against the symptoms and conse-
quences of the disease [37]. Increased awareness of
fibromyalgia as a genuine condition along with practice-
oriented diagnostic criteria and a scale for the assess-
ments of symptom severity [38], will hopefully lead to
more prompt diagnosis and adequate treatment.
The IMMPACT group suggested that 50% improve-
ment in pain intensity is ‘substantial improvement’ [23].
Other evidence suggests that 30 mm is a suitable cut-off
to determine a target pain state [24,25]. Our findings on
time off work and interference with work underline the
usefulness of these suggested cut-offs in clinical practice.
Our analysis provides further evidence that benefit
due to treatment of fibromyalgia with pregabalin across
different domains of life occurs largely in the same
patients, as we previously suggested [14]. Those patients
with the lowest end of trial pain levels and the most
pain improvements had the largest benefits regarding
work. This underlines the point that effective pain treat-
ment should be sought, both from a patient perspective
and also from an economic perspective [39], and that
pain outcomes are linked with outcomes in other
domains of life. Achieving the state of effective pain
control will probably involve changing therapy in a sub-
stantial number of patients because no therapy works
well in more than half the patients with fibromyalgia
[40-42]. Therefore, always using just one drug for treat-
ing this complex and varied condition, even if it appears
best on a population level, is unlikely to deliver the best
outcomes for the most patients.
We found that data from several questions about time
off work and interference with work with somewhat dif-
ferent wording and from different questionnaires yielded
overall similar results, though when expressed as per-
cent improvement in scores (comparing trial beginning
and end, Tables 3 and 4) there were differences in the
magnitude of the improvement. Caution is therefore
needed when data from different work-related questions
are compared. The preliminary findings here would
indicate that questionnaires with 0-10 or 1-10 scales
Table 4 Improvement in answers to work-related questions according to pain state
Pain state (VAS
score)
FIQ (days of work
missed)
FIQ (interference with
work)
SF-36 (interference with
work)
SDS (interference with
work)
MAF (interference with
work)
≤ 30 mm 61 56 41 68 58
30 - 50 mm 41 28 22 46 37
>5 0m m 9.9 7.1 5.9 12 6.2
Percent improvement in answers to work-related questions over the duration of the trials; patients were categorised according to pain state (0-100 mmV A S
score) at the end of trial; FIQ - Fibromyalgia Impact Questionnaire, SF-36 - Short Form 36 Health Survey, SDS - Sheehan Disability Scale, MAF - Multidimensional
Assessment of Fatigue.
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improvements in work interference measures than a
questionnaire with a 1-5 scale. This may be an effect of
the scales, because the maximum possible reduction
that can be attained on a 1-5 scale is 80%, while it is
90% on a 1-10 scale and 100% on a 0-10 scale.
Despite the large number of patients studied in four
high quality randomised trials, the analysis presented
here has important limitations, not least being a retro-
spective analysis that is only hypothesis-generating. As
mentioned previously, using component questions of
questionnaires in this way was not intended by the
developers of the questionnaires, and the question-
naires have therefore not been validated for this use.
Furthermore, the wording of the questions addressing
‘interference with work’ does not allow a differentia-
tion into what kind of ‘interference’ (absenteeism, pre-
senteeism) is present. We had no objective records of
time at work or time off work on which to base our
analysis; nor did we have a detailed description of the
type of occupation. This would have been interesting
because different kinds of occupation may be differ-
ently affected by pain and its treatment. Moreover, we
only used data from four trials of pregabalin in fibro-
myalgia where we had individual data available; other
chronic pain conditions and treatments might produce
different results.
These limitations determine the agenda for future
research: The first step would be a repetition of this
type of analysis for different work-related questions,
different treatments and different chronic pain condi-
tions to determine whether or not our findings are
general. Because data on time off work and interfer-
ence with work are commonly collected in chronic
pain trials, this is primarily a question of obtaining
access to the data and performing the analyses. The
second step will be more difficult: to collect more
detailed information on occupation and objective data
on time off work as part of clinical trials in chronic
p a i n .W eh o p et h a tr a i s i n gt h ea w a r e n e s so ft h e s e
issues will lead to such data being collected in chronic
pain trials in the future.
Conclusions
This meta-analysis of individual patient data from four
trials of pregabalin for fibromyalgia demonstrates that
effective pain treatment, described in terms of pain
improvement over the course of the trials and end of
trial pain state, is linked with benefit regarding work. A
reduction in time off work of more than one day per
week can be achieved in patients with good pain
responses. Analysing answers to work-related compo-
nent questions from different questionnaires yields qua-
litatively similar results.
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